Comorbidities were common in participants with multiple sclerosis (MS) and appeared to be associated with outcomes, including likelihood of relapse and accumulation of new lesions.
Why this matters
It is well known that comorbidities influence the severity of disability at diagnosis and the rate of disability worsening through disease, yet many clinical trials of disease modifying therapies for MS exclude participants with severe comorbidities.
The comorbidity profile of patients may influence clinical trial findings in unpredictable ways and, as stated by the International Advisory Committee on Clinical Trials in MS, there is an unmet need for “the comorbidity status of enrolled clinical trial participants [to] be clearly and consistently described”.
This study provides an important insight into this often-overlooked aspect of MS clinical trial populations.